Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hamdalla, H.
Right arrow Articles by Steinhubl, S. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Hamdalla, H.
Right arrow Articles by Steinhubl, S. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Clinical efficacy of clopidogrel across the whole spectrum of indications: percutaneous coronary intervention

Hussam Hamdalla and Steven R. Steinhubl*

Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA

* Corresponding author: 900 S. Limestone Street, 326 C.T. Wethington Building, Lexington, KY 40536-0200, USA. Tel: +1 859 323 8040; fax: +1 859 323 6475. E-mail address: steinhubl{at}uky.edu

Over the past few decades, the interventional cardiology field has witnessed remarkable progress that demanded an evolution in the adjunctive antithrombotic therapy. Antiplatelet therapy has evolved from simply aspirin into the current use of dual- or even triple-antiplatelet therapy to attenuate the periprocedural ischemic events. Our knowledge and understanding of the use of the current antiplatelet therapy has been further refined with recent landmark trials involving clopidogrel. Dual antiplatelet therapy, with aspirin and clopidogrel, has become standard of care following PCI with stenting. Several trials including PCI-CURE, CREDO and the ISAR trials have established the benefit of pretreatment with clopidogrel in PCI. Although the use of a prolonged course of dual antiplatelet therapy is currently driven primarily by the wide use of drug-eluting stents, it also has been proven to significantly decrease recurrent thrombotic events in the year following PCI unrelated to the target lesion. In this paper we review some of the recent information on the early and long-term use of clopidogrel in the percutaneous coronary intervention patient.

Key Words: Clopidogrel • Antiplatelet therapy • Percutaneous coronary intervention • Cardiovascular disease • Acute coronary syndrome • PCI-CURE • CREDO • PCI-CLARITY


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch SurgHome page
J. M. O'Riordan, R. J. Margey, G. Blake, and P. R. O'Connell
Antiplatelet Agents in the Perioperative Period
Arch Surg, January 1, 2009; 144(1): 69 - 76.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.